Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Study (Journal article)
Fountzilas, G./ Polichronis, A./ Katsohis, K./ Gennatas, K./ Toussis, D./ Skarlos, D./ Kosmidis, P./ Vassilaros, S./ Semoglou, C./ Giannakakis, T./ Fahantidis, E./ Klouvas, G./ Tsavaris, N./ Konstantaras, C./ Makrantonakis, P./ Kolotas, C./ Zamboglou, N./ Tsiliakos, S./ Hainoglou, D./ Mylonakis, N./ Pavlidis, N.
362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 mg/m2), and fluorouracil (500 mg/m2; CNF). After a median follow-up of 51 months, 64 (36%) patients relapsed in the CMF group and 60 (33%) in the CNF group (p=0.8276). By Cox multivariate analysis, tumor size, menopausal status and number of involved nodes were retained as independently significant variables. Toxicities were remarkably similar in both groups. It appears that after a median follow-up of 51 months there is no significant difference in relapse-free survival between node-positive patients with breast cancer who received either 6 cycles of the conventional CMF or the CNF combination as adjuvant treatment.
|Institution and School/Department of submitter:||Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής|
|Keywords:||Adult,Aged,Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use,Breast Neoplasms/*drug therapy/mortality/pathology,Chemotherapy, Adjuvant,Cyclophosphamide/administration & dosage/adverse effects,Female,Fluorouracil/administration & dosage/adverse effects,Follow-Up Studies,Humans,Methotrexate/administration & dosage/adverse effects,Middle Aged,Mitoxantrone/administration & dosage/adverse effects,Remission Induction,Survival Rate|
|Appears in Collections:||Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)|
Files in This Item:
There are no files associated with this item.
Please use this identifier to cite or link to this item:This item is a favorite for 0 people.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.